Retinoids are the most evidence-backed topical ingredient in dermatology

Prescription retinoids have the strongest evidence base of any topical skincare ingredient. They work through nuclear receptor signaling, accelerating cell turnover, stimulating collagen, and normalizing melanin distribution at the gene expression level.

Mechanism of action

Retinoids are derivatives of Vitamin A. They exert their effects by binding to nuclear receptors. Specifically, retinoic acid receptors (RARs) and retinoid X receptors (RXRs), which function as transcription factors, directly regulating gene expression in skin cells.

The downstream effects are broad: retinoids accelerate epidermal cell turnover (normalizing the slower renewal of aged skin), stimulate fibroblast activity and collagen Type I production, inhibit MMP expression (reducing collagen degradation), and normalize melanocyte function (reducing hyperpigmentation). They also promote differentiation of keratinocytes, making them one of the most effective treatments for acne.

Prescription retinoids versus over-the-counter retinol

Active retinoic acid (tretinoin) binds directly to RARs. Retinol (the OTC form) requires two enzymatic conversion steps. First to retinaldehyde, then to retinoic acid before exerting its effect. Each conversion step introduces attrition: not all retinol is successfully converted, and the process is inefficient. Prescription-grade tretinoin is approximately 20× more potent than OTC retinol at equivalent concentrations, not because the molecule is different, but because it doesn’t require the conversion pathway.

FORM	CONVERSION REQUIRED	RELATIVE POTENCY	AVAILABILITY
Tretinoin (Retin-A)	None, active form	Reference standard	Prescription
Tazarotene	One step (pro-drug)	Stronger than tretinoin	Prescription
Adapalene 0.3%	None, active form	Slightly less than tretinoin	Prescription
Retinaldehyde	One step	~5 to 10× weaker than tretinoin	OTC (cosmetic)
Retinol	Two steps	~20× weaker than tretinoin	OTC (cosmetic)

How to use retinoids effectively

Initial dryness, peeling, and mild redness are expected with prescription retinoids and indicate the product is working. These are signs of accelerated cell turnover, the epidermis renewing faster than it is accustomed to. They typically resolve within 4 to 6 weeks as the skin adapts.

Start with the lowest available concentration, 2 to 3 nights per week, and increase frequency gradually. Apply to dry skin (wet skin increases penetration and irritation). A pea-sized amount for the whole face is sufficient. Follow with a fragrance-free moisturizer. Morning SPF is essential, because retinoids increase photosensitivity and their anti-aging benefits are undermined by UV exposure.

ON THE INITIAL “PURGE”

Accelerated cell turnover in the early weeks can transiently worsen acne as follicular contents are expelled more rapidly. This typically resolves within 4 to 8 weeks and is a sign the product is working, not a reason to stop. Reducing frequency temporarily can manage the reaction without abandoning the treatment.

Using retinoids alongside clinical treatments

Retinoids should be paused for 3 to 5 days before and 5 to 7 days after microneedling, polynucleotide, or PRP treatments: their action on cell turnover and skin sensitivity increases the risk of excessive irritation in post-treatment skin. Full resumption can typically occur within a week.

Outside of treatment recovery windows, retinoids and clinical treatments are highly complementary, addressing skin quality at the topical and dermal levels simultaneously. Patients using consistent retinoids alongside periodic clinical treatments generally achieve better long-term outcomes than either approach alone.

References

Kang S, Li XY, Voorhees JJ. Pharmacology and molecular action of retinoids and vitamin D in skin. J Investig Dermatol Symp Proc. 1996;1(1):15-21. PMID 9627686.
Zasada M, Budzisz E. Retinoids: active molecules influencing skin structure formation in cosmetic and dermatological treatments. Postepy Dermatol Alergol. 2019;36(4):392-397. PMID 31616211.
Griffiths CE, Russman AN, Majmudar G, et al. Restoration of collagen formation in photodamaged human skin by tretinoin (retinoic acid). N Engl J Med. 1993;329(8):530-535. PMID 8336752.
Fisher GJ, Wang ZQ, Datta SC, et al. Pathophysiology of premature skin aging induced by ultraviolet light. N Engl J Med. 1997;337(20):1419-1428. PMID 9358139.
Kang S, Duell EA, Fisher GJ, et al. Application of retinol to human skin in vivo induces epidermal hyperplasia and cellular retinoid binding proteins characteristic of retinoic acid but without measurable retinoic acid levels or irritation. J Invest Dermatol. 1995;105(4):549-556. PMID 7561157.
Phillips TJ, Gottlieb AB, Leyden JJ, et al. Efficacy of 0.1% tazarotene cream for the treatment of photodamage: a 12-month multicenter, randomized trial. Arch Dermatol. 2002;138(11):1486-1493. PMID 12437455.
Bagatin E, Gonçalves HS, Sato M, et al. Comparable efficacy of adapalene 0.3% gel and tretinoin 0.05% cream as treatment for cutaneous photoaging. Eur J Dermatol. 2018;28(3):343-350. PMID 30105991.
Mukherjee S, Date A, Patravale V, et al. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006;1(4):327-348. PMID 18046911.